First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference
03 mars 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
14 oct. 2021 09h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Two Additions to Scientific Advisory Board
12 oct. 2021 08h30 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...